Suchergebnisse - "Shah, Rashmi R"

PubPharm (147)

41

CYP450 genotype and pharmacogenetic association studies : a critical appraisal

enthalten in: Pharmacogenomics | 2016

von Shah, R. | Gaedigk, A. | LLerena, A. | +3

42

CYP450 genotype and pharmacogenetic association studies: a critical appraisal

enthalten in: Pharmacogenomics | 2016

von Smith, R. | Eichelbaum, M. | Stingl, J. | +3

43

Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas

enthalten in: Drug safety | 2016

von Shah, R.

44

Establishing assay sensitivity in QT studies : experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study

enthalten in: European journal of clinical pharmacology | 2015

von Shah, R. | Maison-Blanche, P. | Duvauchelle, T. | +2

45

Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study

enthalten in: European journal of clinical pharmacology | 2015

von Shah, R. | Maison-Blanche, P. | Duvauchelle, T. | +2

46

Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study

enthalten in: European journal of clinical pharmacology | 2015

von Shah, R. | Maison-Blanche, P. | Duvauchelle, T. | +2

47

Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study

enthalten in: European journal of clinical pharmacology | 2015

von Shah, R. | Maison-Blanche, P. | Duvauchelle, T. | +2

48

Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors : With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit

enthalten in: Drug safety | 2015

von Shah, R. | Morganroth, J.

49

Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit

enthalten in: Medical toxicology | 2015

von Shah, R. | Morganroth, J.

50

Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit

enthalten in: Drug safety | 2015

von Shah, R. | Morganroth, J.